1. Home
  2. HALO vs REG Comparison

HALO vs REG Comparison

Compare HALO & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$108.26

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Logo Regency Centers Corporation

REG

Regency Centers Corporation

HOLD

Current Price

$74.39

Market Cap

14.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
REG
Founded
1998
1963
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
14.0B
IPO Year
2001
1994

Fundamental Metrics

Financial Performance
Metric
HALO
REG
Price
$108.26
$74.39
Analyst Decision
Buy
Buy
Analyst Count
11
15
Target Price
$78.64
$80.07
AVG Volume (30 Days)
1.4M
989.2K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
3.80%
EPS Growth
N/A
N/A
EPS
3.11
0.46
Revenue
$151,862,000.00
$1,553,524,000.00
Revenue This Year
$28.24
$3.04
Revenue Next Year
$12.56
$4.52
P/E Ratio
$34.47
$162.22
Revenue Growth
N/A
6.85
52 Week Low
$61.23
$66.86
52 Week High
$111.15
$83.66

Technical Indicators

Market Signals
Indicator
HALO
REG
Relative Strength Index (RSI) 64.98 40.06
Support Level $103.47 $74.42
Resistance Level $111.15 $76.97
Average True Range (ATR) 2.33 0.84
MACD -1.06 0.05
Stochastic Oscillator 59.05 26.64

Price Performance

Historical Comparison
HALO
REG

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About REG Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

Share on Social Networks: